检索结果-南通市图书馆

Protective effects of a novel drug RC28-E blocking both VEGF and FGF2 on early diabetic rat retina

International Journal of Ophthalmology(English edition) 2018年第6期11卷 935-944页

作者： Qian-Hui Yang Yan Zhang Jing Jiang Mian-Mian Wu Qian Han Qi-Yu Bo Guang-Wei Yu Yu-Sha Ru Xun Liu Min Huang Ling Wang Xiao-Min Zhang Jian-Min Fang Xiao-Rong Li Tianjin Medical University Eye Hospital Tianjin Medical University Eye Institute College of Optometry and Ophthalmology Tianjin Medical University School of Pharmacy Binzhou Medical University remegen Ltd. School of Life Sciences and Technology Tongji University

AIM： To investigate protective effects of a novel recombinant decoy receptor drug RC28-E on retinal damage in early diabetic rats. METHODS： The streptozotocin （STZ）-induced diabetic rats were randomly divided into 6 groups： diabetes mellitus （DM） group （saline, 3 μL/eye）; RC28-E at low （0.33 μg/μL, 3 μL）, medium （1 μg/μL, 3 μL）, and high （3 μg/μL, 3 μL） dose groups; vascular endothelial growth factor （VEGF） Trap group （1 μg/μL, 3 μL）; fibroblast growth factor （FGF） Trap group （1 μg/μL, 3 μL）. Normal control group was included. At week 1 and 4 following diabetic induction, the rats were intravitreally injected with the corresponding solutions. At week 6 following the induction, apoptosis in retinal vessels was detected by TUNEL staining. Glial fibrillary acidic protein （GFAP） expression was examined by immunofluorescence. Blood-retinal barrier （BRB） breakdown was assessed by Evans blue assay. Ultrastructural changes in choroidal and retinal vessels were analyzed by transmission electron microscopy （TEM）. Content of VEGF and FGF proteins in retina was measured by enzyme linked immunosorbent assay （ELISA）. The retinal expression of intercellular cell adhesion molecule-1 （ICAM-1）, tumor necrosis factor-α （TNF-α）, VEGF and FGF genes was examined by quantitative polymerase chain reaction （qPCR）. RESULTS： TUNEL staining showed that the aberrantly increased apoptotic cells death in diabetic retinal vascular network was significantly reduced by treatments of medium and high dose RC28-E, VEGF Trap, and FGF Trap （all P〈0.05）, the effects of medium and high dose RC28-E or FGF Trap were greater than VEGF Trap （P〈0.01）. GFAP staining suggested that reactive gliosis was substantially inhibited in all RC28-E and VEGF Trap groups, but the inhibition in FGF Trap group was not as prominent. Evans blue assay demonstrated that only high dose RC28-E could significantly reduce vascular leakage in early diabetic retina （P〈0.01）. TEM revealed that the ultrastructures in choroidal and retinal vessels were damaged in early di

关键词： diabetic retinopathy vascular endothelialgrowth factor fibroblast growth factor 2 recombinant decoy receptor retinal damage diabetes

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing,locally advanced or metastatic gastric or gastroesophageal junction cancer:a single-arm phase II study

引用

Cancer Communications 2021年第11期41卷 1173-1182页

作者： Zhi Peng Tianshu Liu Jia Wei Airong Wang Yifu He Liuzhong Yang Xizhi Zhang Nanfeng Fan Suxia Luo Zhen Li Kangsheng Gu Jianwei Lu Jianming Xu Qingxia Fan Ruihua Xu Liangming Zhang Enxiao Li Yuping Sun Guohua Yu Chunmei Bai Yong Liu Jiangzheng Zeng Jieer Ying Xinjun Liang Nong Xu Chao Gao Yongqian Shu Dong Ma Guanghai Dai Shengmian Li Ting Deng Yuehong Cui Jianmin Fang Yi Ba Lin Shen Department of Gastrointestinal Oncology Key Laboratory of Cancinogenesis and Translational Research(Ministry of Education)Peking University Cancer Hospital&InstituteBeijing 100142P.R.China Department of Gastrointestinal Oncology Affiliated Zhongshan Hospital of Fudan UniversityShanghai 200032P.R.China Department of Oncology Nanjing Drum Tower Hospitalthe Affiliated Hospital of Nanjing University Medical SchoolNanjingJiangsu 210008P.R.China Department of Oncology Weihai Municipal HospitalWeihaiShandong 264299P.R.China Department of Oncology Anhui Provincial Cancer HospitalHefeiAnhui 230031P.R.China Department of Oncology The First Affiliated Hospital of Xinxiang Medical CollegeXinxiangHenan 453100P.R.China Department of Oncology Subei People’s HospitalYangzhouJiangsu 225009P.R.China Department of Abdominal Oncology Fujian Provincial Cancer HospitalFuzhouFujian 350014P.R.China Department of Gastrointestinal Oncology Henan Cancer HospitalZhengzhouHenan 450003P.R.China Department of Oncology Linyi Cancer HospitalLinyiShandong 276002P.R.China Department of Oncology The First Affiliated Hospital of Anhui Medical UniversityHefeiAnhui 230022P.R.China Department of Oncology Jiangsu Cancer HospitalNanjingJiangsu 210009P.R.China Department of Oncology The Fifth Medical Center of PLA General HospitalBeijing 100039P.R.China Department of Oncology The First Affiliated Hospital of ZhengzhouZhengzhouHenan 450099P.R.China Department of Oncology Sun Yat-sen University Cancer CenterGuangzhouGuangdong 510060P.R.China Department of Oncology Yantai Yuhuangding HospitalYantaiShandong 264099P.R.China Department of Oncology The First Affiliated Hospital of Xi’an Jiaotong UniversityXi’anShanxi 710061P.R.China Department of Oncology Jinan Central HospitalJinanShandong 250013P.R.China Department of Oncology Weifang People’s HospitalWeifangShandong 261041P.R.China Department of Oncology Peking Union Medical College HospitalBeijing 100005P.R.China Department of Oncology Xuzhou Central

Background:Current treatment options for human epidermal growth factor receptor 2(HER2)-overexpressing gastric cancer at third-line have shown limited clinical benefit.Further,there is no specific treatment for HER2 immunohistochemistry(IHC)2+and fluorescence in-situ hybridization-negative patients.Here,we report the efficacy and safety of a novel anti-HER2 antibody RC48 for patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer.Methods:Patients with HER2-overexpressing(IHC 2+or 3+),locally advanced or metastatic gastric or gastroesophageal junction cancer who were under at least second-line therapy were eligible and received RC482.5 mg/kg alone every 2 weeks.The primary endpoint was the objective response rate(ORR)assessed by an independent review committee.Secondary endpoints included progressionfree survival(PFS),overall survival(OS),duration of response,time to progression,disease control rate,and safety.Results:Of 179 patients screened,125 were eligible and received RC48 treatment.The ORR was 24.8%(95%confidence interval[CI]:17.5%-33.3%).The median PFS and OS were 4.1 months(95%CI:3.7-4.9 months)and 7.9 months(95%CI:6.7-9.9 months),respectively.The most frequently reported adverse events were decreased white blood cell count(53.6%),asthenia(53.6%),hair loss(53.6%),decreased neutrophil count(52.0%),anemia(49.6%),and increased aspartate aminotransferase level(43.2%).Serious adverse events(SAEs)occurred in 45(36.0%)patients,and RC48-related SAEs were mainly decreased neutrophil count(3.2%).Seven patients had adverse events that led to death were not RC48-related.Conclusions:RC48 showed promising activity with manageable safety,suggesting potential application in patients with HER2-overexpressing,advanced gastric or gastroesophageal junction cancer who have previously received at least two lines of chemotherapy.

关键词： antibody-drug conjugate gastric cancer HER2-overexpressing phase II clinical trial RC48 third-line therapy

来源：

维普期刊数据库评论

在线全文

维普期刊数据库

学校读者我要写书评

暂无评论

欢迎您,

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案：

请选择收藏分类：

通借通还

欢迎您,

建议与咨询 留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

时间限定

文献类型

馆藏选择

核心期刊

语言

文献类型

帮助

文字说明：

检索规则说明：

检索范例：

分类表

所选分类

限定检索结果

文献类型

馆藏范围

日期分布

学科分类号

主题

机构

作者

语言

在线全文

在线全文

请选择保存的检索档案： 新增检索档案 确定 取消

请选择收藏分类： 新增自定义分类 确定 取消

通借通还

建议与咨询留下您的常用邮箱和电话号码，以便我们向您反馈解决方案和替代方法

请选择保存的检索档案：

请选择收藏分类：